Imricor Medical Systems Stock Working Capital
| IMR Stock | 1.44 0.01 0.70% |
Imricor Medical Systems fundamentals help investors to digest information that contributes to Imricor Medical's financial success or failures. It also enables traders to predict the movement of Imricor Stock. The fundamental analysis module provides a way to measure Imricor Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Imricor Medical stock.
Change In Working Capital is likely to gain to about 3.5 M in 2025, despite the fact that Net Working Capital is likely to grow to (537.1 K). Imricor | Working Capital |
Imricor Medical Systems Company Working Capital Analysis
Imricor Medical's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Imricor Medical Working Capital | (628.21 K) |
Most of Imricor Medical's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Imricor Medical Systems is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Imricor Capital Surpluse
Capital Surpluse |
|
According to the company's disclosures, Imricor Medical Systems has a Working Capital of (628,208). This is 100.15% lower than that of the Health Care Equipment & Supplies sector and 100.05% lower than that of the Health Care industry. The working capital for all Australia stocks is 100.04% higher than that of the company.
Imricor Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Imricor Medical's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Imricor Medical could also be used in its relative valuation, which is a method of valuing Imricor Medical by comparing valuation metrics of similar companies.Imricor Medical is currently under evaluation in working capital category among its peers.
Imricor Fundamentals
| Return On Equity | -2.75 | ||||
| Return On Asset | -1.25 | ||||
| Operating Margin | (19.77) % | ||||
| Current Valuation | 404.88 M | ||||
| Shares Outstanding | 270.18 M | ||||
| Shares Owned By Insiders | 20.26 % | ||||
| Shares Owned By Institutions | 14.56 % | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 471.97 X | ||||
| Revenue | 615.57 K | ||||
| Gross Profit | (913.44 K) | ||||
| EBITDA | (21.87 M) | ||||
| Net Income | (22.63 M) | ||||
| Total Debt | 10.42 M | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (19.55 M) | ||||
| Earnings Per Share | (0.18) X | ||||
| Target Price | 1.56 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 389.05 M | ||||
| Total Asset | 8.31 M | ||||
| Retained Earnings | (165 M) | ||||
| Working Capital | (628.21 K) | ||||
| Net Asset | 8.31 M |
About Imricor Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Imricor Medical Systems's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Imricor Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Imricor Medical Systems based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Imricor Stock Analysis
When running Imricor Medical's price analysis, check to measure Imricor Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imricor Medical is operating at the current time. Most of Imricor Medical's value examination focuses on studying past and present price action to predict the probability of Imricor Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imricor Medical's price. Additionally, you may evaluate how the addition of Imricor Medical to your portfolios can decrease your overall portfolio volatility.